IONS vs. BIIB, UTHR, INCY, NBIX, EXEL, BMRN, EXAS, MDGL, HALO, and RGEN
Should you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), and Repligen (RGEN). These companies are all part of the "biotechnology" industry.
Ionis Pharmaceuticals vs. Its Competitors
Ionis Pharmaceuticals (NASDAQ:IONS) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.
Ionis Pharmaceuticals presently has a consensus target price of $75.29, suggesting a potential upside of 9.22%. Biogen has a consensus target price of $180.04, suggesting a potential upside of 18.28%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Ionis Pharmaceuticals.
In the previous week, Ionis Pharmaceuticals had 7 more articles in the media than Biogen. MarketBeat recorded 25 mentions for Ionis Pharmaceuticals and 18 mentions for Biogen. Biogen's average media sentiment score of 0.97 beat Ionis Pharmaceuticals' score of 0.21 indicating that Biogen is being referred to more favorably in the news media.
Ionis Pharmaceuticals has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500.
Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
Biogen has a net margin of 15.31% compared to Ionis Pharmaceuticals' net margin of -28.25%. Biogen's return on equity of 13.85% beat Ionis Pharmaceuticals' return on equity.
93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 2.7% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Biogen beats Ionis Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Ionis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ionis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:IONS) was last updated on 10/8/2025 by MarketBeat.com Staff
